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Abstract
Background: Lung cancer is the leading cause of cancer-related deaths with 1.8 million new cases each year and
poor 5-year prognosis. Promoter hypermethylation of tumour suppressors leads to their inactivation and thereby
can promote cancer development and progression.
Results: In this study, we analysed ZAR1 (zygote arrest 1), which has been said to be a maternal-effect gene and its
expression mostly limited to certain reproductive tissues. Our study shows that ZAR1 is expressed in normal lung
but inactivated by promoter methylation in lung cancer. ZAR1 is hypermethylated in primary lung cancer samples
(22% small cell lung carcinoma (SCLC) and 76% non-small cell lung carcinoma (NSCLC), p < 0.001) vs. normal
control lung tissue (11%). In lung cancer cell lines, ZAR1 was significantly methylated in 75% of SCLC and 83% of
NSCLC vs. normal tissue (p < 0.005/0.05). In matching tumours and control tissues, we observed that NSCLC primary
tumour samples exhibited a tumour-specific promoter methylation of ZAR1 in comparison to the normal control
lung tissue. Demethylation treatment of various lung cancer cell lines reversed ZAR1 promoter hypermethylation
and subsequently re-established ZAR1 expression. In addition, we could show the growth inhibitory potential of
ZAR1 in lung cancer cell lines and cancer cell lines. Exogenous expression of ZAR1 not only inhibited colony
formation but also blocked cell cycle progression of cancer cell lines.
Conclusions: Our study shows for the first time the lung tumour-specific epigenetic inactivation of ZAR1 due to
DNA methylation of its CpG island promoter. Furthermore, ZAR1 was characterised by the ability to block tumour
growth through the inhibition of cell cycle progression in cancer cell lines. We propose that ZAR1 could serve as an
epigenetically inactivated biomarker in lung cancer.
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Background
Lung cancer is currently the leading cause of cancer re-
lated deaths in men and the second leading cause of
cancer death in women worldwide [1]. Lung cancer has
a high incidence coupled with a poor 5-year survival rate
of less than 17% [2]. In 2012, 1.8 million cases were
newly diagnosed worldwide and 1.6 million deaths from
lung cancer occurred [3]. Tobacco smoking still is the
main cause for lung cancer development [4]. Lung
cancer can be classified histologically as small cell lung
carcinoma (SCLC, 20% of cases) and non-small cell lung
carcinoma (NSCLC, 80% of cases), and NSCLC can
further be divided into adenocarcinoma, squamous cell
carcinoma, and large cell carcinoma subtypes [5]. Lung
cancer treatment as well as prognosis differ depending
on lung cancer subtypes [6]. There are a plethora of
known lung cancer associated genomic and epigenetic
alterations, and it was summarised that epigenetic mod-
ulators, modifiers, and mediators play a crucial role in
lung cancer initiation and progression [5, 7].
Our own experiments regarding lung cancer analysed
epigenetic alterations in the lung cancer cell line A549
using the Infinium HumanMethylation450K BeadChip
Array (Illumina). We found the maternal effect gene
ZAR1 was one of the best candidates [8]. Human ZAR1
or zygote arrest 1 is located on chromosome 4 (4p11)
and covered by a 1.5 kb large CpG island (Additional file
1: Figure S1). CpG islands are genomic regions defined
by the enrichment of CpG dinucleotides [9]. ZAR1’s
1275 nt transcript from 4 exons encodes 424 amino acid
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proteins containing a C-terminal zinc finger (CpG plot,
NCBI and UCSC genome browser).
ZAR1 was described as a novel maternal-effect gene
critical for oocyte to embryo transition in mouse and es-
pecially the C-terminus of its protein is evolutionarily
highly conserved in vertebrates [10, 11], but later studies
found that its expression was not limited to the oocyte
[12–14].
Regarding an association of human ZAR1 and cancer
only, few reports exist. In malignant melanoma, ZAR1
was intra-genically methylated (exon 1) and ZAR1 was
overexpressed in some hypermethylated melanoma cell
lines [15]. Non-promoter hypermethylation was found in
brain tumours and neuroblastoma [16, 17]. Expression
of ZAR1 was absent in hypermethylated glioma cell lines
[16], but ZAR1 was detected in hypermethylated neuro-
blastoma [17]. It was proposed that methylation-related
aberrant ZAR1 expression was unlikely to be related to
glioma tumorigenesis [16]. ZAR1 intragenic methylation
(first exon to intron 1) in sporadic bladder cancer was
decreased in high-grade vs. low-grade tumours [18]. In
hepatitits C virus, positive hepatocellular carcinoma
ZAR1 hypermethylation of exon 1 was found [19]. These
previous data concentrated on non-promoter methyla-
tion and ZAR1 expression levels were inconsistent.
We hypothesised that ZAR is a tumour suppressor
inactivated in cancer by its promoter hypermethylation.
In our study, we found that ZAR1 is epigenetically inac-
tivated in lung cancer. We further found evidence that
ZAR1 acts as a tumour suppressor and therefore suggest
it could serve as a biomarker in lung cancer cells.
Results
ZAR1 is epigenetically inactivated in lung cancer
In an Infinium HumanMethylation450K BeadChip Array
(Illumina), we observed altered promoter methylation of
the lung cancer cell line A549 [8]. ZAR1 (zygote arrest
1) was amongst the most strongly deregulated genes,
and up to date, no study investigated the epigenetic in-
activation of the ZAR1 promoter and its consequences
in lung cancer. We found that ZAR1 is expressed in
normal lung (Fig. 1b), but its expression is lost in lung
cancer cell lines (Fig. 1a, b). Studying the genomic or-
ganisation of ZAR1, we found a CpG island of 1.5 kb,
which covered the promoter and its first exon (Add-
itional file 1: Figure S1). ZAR1 is encoded by four exons,
it contains 424 aa and an uncharacteristic C-terminal
zinc finger. In ZAR1’s structure, we could not find an
NLS signal and in accordance, it was said that ZAR’s
zinc finger possibly facilitates RNA binding [20].
In our epigenetic work on ZAR1, we investigated the
connection of promoter hypermethylation and repres-
sion of expression in the context of lung cancer. For
promoter hypermethylation analysis, we chose bisulfite
treatment and subsequent restriction analysis with TaqI
enzyme (COBRA; combined bisulfite restriction analysis)
and pyrosequencing for quantification (Additional file 1:
Figure S1, target CpGs are shown). ZAR1 expression
was undetectable in various lung cancer cell lines as
A427, A549 and H322, HTB171 and also in HeLa cervix
cancer cells. H358 lung cancer cells however expressed
ZAR1 (Fig. 1a, b). In normal control tissues from an
RNA panel, we found that ZAR1 was detectable in the
lung (set 100%), but relatively low (<10%) in breast, kid-
ney, liver and heart. All lung cancer cell lines exhibited
decreased ZAR1 levels (<5%) vs. normal lung, except for
H358, which was 15% (Fig. 1b). In lung cancer cell lines
(A247, A549, HTB171, H322, H1299) and HEK cells, the
ZAR1 promoter was highly methylated as analysed by
COBRA, in HeLa and H358 lung cancer cells partially
methylated and in HCC-15 lung cancer cells unmethy-
lated (Figs. 1c and 4a). The according quantification by
pyrosequencing (Fig. 1d) confirmed the COBRA results
and found methylation levels between 78 and 93% for
A427, A549, HEK, HTB171 and H322 and partial pro-
moter methylation of 50% for H358. An unmethylated
sample (SC26, Fig. 3a) was used as a negative control
(Fig. 1d). We then investigated ZAR1 promoter hyper-
methylation by COBRA in a set of non-small cell lung
cancer (NSCLC) and small cell lung cancer cells (SCLC)
from cell lines and primary tumour samples (Additional
file 2: Table S1). In SCLC cell lines, we observed ZAR1
promoter hypermethylation in 15 out of 20 samples
(75%), and in the smaller set of NSCLC, five of six sam-
ples (83%) were methylated (Figs. 1, 2, 3c and 4a and
Additional file 2: Table S1 and Additional file 3: Table
S2). In primary tumour samples from SCLC, the ZAR1
promoter was methylated in 5 out of 23 (22%) and in
NSCLC, 16 out of 21 (76%) (Fig. 3 and Additional file 2:
Table S1 and Additional file 3: Table S2). Control tissues
of SCLC and NSCLC tumour samples were mostly
unmethylated (11%; Fig. 3, Additional file 2: Table S1
and Additional file 3: Table S2). ZAR1 promoter methy-
lation increased from matching control tissues to
tumour samples (LT1 to LN1, LT3 to LN3, LT39 to
LN39, Fig. 3b).
Our findings showed a strong methylation of the
ZAR1 promoter, and we therefore aimed to test the epi-
genetic inactivation of ZAR1 by reversal of promoter
methylation. We chose lung cancer cell lines with ZAR1
promoter hypermethylation for demethylation treatment
in cell culture. 5-Aza-2’-deoxycytidine (Aza) is an inhibi-
tor of DNA methyltransferases and demethylating agent.
It was used to reverse promoter methylation and thereby
verify the epigenetic inactivation of ZAR1. ZAR1 methyl-
ated cell lines HEK, NSCLC cell lines A549, A427,
H1299, H358, H322 and SCLC cell line HTB171 exhib-
ited promoter demethylation with 5 or 10 μM Aza
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treatment, but unmethylated HCC-15 (NSCLC)
remained unaffected (Fig. 4a). An in vitro methylated
DNA was used as a positive control for.
Cancer cell lines (A427, A549, H322, HTB171 and
HeLa) with ZAR1 promoter hypermethylation (Figs. 1c,
d and 4a) and missing ZAR1 expression (Fig. 1a, b) were
chosen for testing reexpression of ZAR1 under demeth-
ylation treatment. All tested cancer cell lines showed en-
dogenous reexpression of ZAR1 with 5 μM Aza and
further increased expression under 10 μM Aza in a
semiquantitative PCR (Fig. 4b), which was consistent
when quantified for 5 μM Aza by real-time PCR (Fig. 4c).
Demethylation treatment restored ZAR1 levels in H322
to almost normal lung expression levels (Fig. 4c). Coher-
ently, the ZAR1 promoter luciferase reporter construct
was significantly silenced by in vitro methylation (ivm)
compared to the unmethylated promoter or the empty
control luciferease reporter construct (Fig. 4d).
a
b
c
d
Fig. 1 ZAR1 expression pattern, missing expression in lung cancer and promoter hypermethylation in lung cancer cell lines. ZAR1 expression in
lung cancer cell lines A427, A549, HTB171, H322, H358 and HeLa (cervix carcinoma) versus normal tissue panel (breast, kidney, liver, lung and
heart) by RT-PCR and semi-/quantitative PCR were determined. a, b Expression levels were normalised to ß-ACTIN (ACTB) and to normal lung tis-
sue (=100%). Promoter hypermethylation of lung cancer cell lines, HEK and HeLa cells by COBRA analysis c and pyrosequencing for quantification
d are shown. PCR and digestion products were separated on 2% TBE agarose gel with 100 bp marker M (m methylated, pm partially methylated,
pos. positive control, neg. negative control; + TaqI digested, − mock digested)
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ZAR1 is a tumour suppressor in human cancer cell lines
Based on our findings that ZAR1 is epigenetically inacti-
vated in lung cancer cell lines and primary lung cancer
tumours, we aimed to test its tumour suppressive prop-
erties. Colony formation assays were performed in A549,
A427 and HTB171 lung cancer cells that are epigeneti-
cally inactivated for ZAR1 (Figs. 1 and 4). ZAR1 reex-
pression reduced colony numbers compared to vector
control in A549 by 89%, in A427 by 71% and in HTB171
by 51% (Fig. 5a). This growth reduction by ZAR1 was
significant for all three lung cancer cell lines when quan-
tified (Fig. 5b). For expression control and determining
ZAR1 localisation, we used EGFP tagged ZAR1. ZAR1 is
found throughout the cytosol, but not within the nu-
cleus, which is exemplarily shown for A549 and HeLa
cells (Fig. 6a, b). We next questioned if the observed
growth inhibition of lung cancer cells by reexpressed
ZAR1 could be due to increased apoptosis or arrest of
cell cycle progression. We chose different cancer cells as
A549 (lung cancer), HeLa (cervix carcinoma) and
HCT116 (colon carcinoma) for reexpression of ZAR1.
We performed flow cytometry analysis using propidium
iodide staining to determine the nuclear DNA content.
Flow cytometry in HeLa cells showed that ZAR1 overex-
pression increased the number of cells in S phase, but at
the same time, no increase in mitosis was observed
(Fig. 6c and Additional file 4: Figure S2A). Likewise,
ZAR1 expression arrested HCT116 cells in S phase
(Fig. 6d, e and Additional file 4: Figure S2C + D) as well
as A549 cells (Additional file 4: Figure S2B).
In summary, we could show the epigenetic inactivation
of ZAR1 in lung cancer for the first time. Additionally,
we characterised the tumour suppressive properties of
ZAR1 in cancer cells. ZAR1 inhibited cancer cell growth
by arresting cell cycle progression.
Discussion
ZAR1 has been studied for a bit more than a decade and
has been reported to be a maternal-effect gene critical
for oocyte-to-embryo transition [10]. Subsequent reports
found that the expression of ZAR1 was not limited to
the oocyte. In cattle [12], pig [13] and chicken [14], the
Zar1 expression pattern differs from mouse and ZAR1
was not only expressed in ovary. ZAR1 is also expressed
in porcine and bovine brain and testis [13], additionally
in bovine heart and muscle [12] and amongst others in
chicken testis [14]. During the course of this project, it
was reported that expression levels of rabbit Zar1 are
highest in lung tissue in comparison to other tissues,
which supports our findings of strong ZAR1 expression
in human lung [21]. However, functionally, there is little
known about ZAR1. ZAR1 female double-knockout
mice are infertile due to developmental failure of their
embryos [10]. In mouse, Cis-acting elements necessary
for oocyte-specific gene expression were found in the
ZAR1 promoter [22]. Concerning xenopus Zar1, it has
Fig. 2 ZAR1 promoter hypermethylation in lung cancer cell lines (SCLC). ZAR1 promoter methylation status was analysed by COBRA assay in
various SCLC lung cancer cell lines. CpG island region from the ZAR1 promoter was amplified from bisulfite-treated DNA and digested with Taq1.
Digestion products indicate ZAR1 promoter methylation. Digestion products were separated on 2% TBE agarose gel with 100 bp marker (m methylated,
um unmethylated, pos. positive control, + TaqI-digested, −mock digested)
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been said to bind to the 3’UTRs in maternal mRNAs
through its zinc finger [20]. In our study, we aimed to
establish ZAR1, which we found as a candidate from a
450 K methylation array, as an epigenetically inactivated
tumour suppressor in human lung cancer.
In our study, we found that ZAR1 was predominantly
expressed in human lung, but relatively lowered in other
tested tissues. This finding was in accordance with data
we analysed from The GTEx Consortium Analysis
Working Group [23], showing that the expression of
ZAR1 is not limited to oocytes in humans. In addition,
we observed the absence of ZAR1 expression in lung
cancer cell lines. This observation prompted us to sus-
pect an epigenetic regulation of ZAR1 and a possible
function of ZAR1 in cancer inhibition. Earlier reports
found non-promoter hypermethylation of ZAR1; how-
ever, a functional consequence was not reported [15–
19]. In contrast, we found promoter hypermethylation of
ZAR1 not only in lung cancer cell lines but also in pri-
mary lung cancer of the SCLC and NSCLC subtype. Fur-
thermore, we could restore ZAR1 expression in lung
cancer cell lines pharmacologically by inhibition of DNA
methyltransferases. Our analyses of ZAR1 therefore de-
fine ZAR1 as a heavily methylated CpG island carrying
gene, which is epigenetically inactivated in lung cancer.
It will be interesting to study the ZAR1 hypermethyla-
tion together with other known lung cancer tumour sup-
pressors, e.g. RASSF1A and RASSF10 [24–28]. Defining
a set of tumour suppressor that are specifically inacti-
vated in lung cancer could serve as a tool for lung can-
cer detection in, e.g. liquid biopsies and as a cancer
prognostic outcome predictor in the future. In larger
sample sets of SCLC and NSCLC as well as lung cancer
metastases, one could narrow the time point when
ZAR1 becomes hypermethylated and inactivated during
lung carcinogenesis.
Interestingly, enhancer of zeste homolog 2 (EZH2), a
part of the Polycomb Repressive Complex 2, was found
to bind to the ZAR1 promoter by ChIPseq as shown by
the UCSC genome browser using the ENCODE project
data (Additional file 5: Figure S3). EZH2 was said to be
required for DNA methylation of EZH2-target pro-
moters [29]. This observation supports the hypothesis
that ZAR1 can be deliberately inactivated by DNA
methylation in cancer. It is already well studied that
methylated DNA in CpG island promoters is associated
with the binding methylated DNA-binding proteins,
which in turn recruit histone deacetylases to the region.
This mechanism holds the promoter in a stably re-
pressed state [30].
We found that overexpressed ZAR1 localised through-
out the cytosol. Where endogenous ZAR1 is localised will
be verified with later experiments when an appropriate
antibody for ZAR1 is available. With this tool on-hand, we
could not only study ZAR1 expression in primary cancer
samples and correlate expression with ZAR1 promoter
methylation but also study interacting partners, which
would give insight into its network and signalling path-
ways. This could elucidate its precise biological function
in somatic lung cells, as to whether it controls prolifera-
tion, could induce apoptosis upon cellular stress and regu-
lates mRNA translatability via binding to 3’UTRs [31]. In
our present study, we further found that ZAR1 inhibited
proliferation irrespective of the cancer type, as we ob-
served ZAR1 blocked growth of three lung cancer cell
lines, a cervix carcinoma and one colon cancer cell line. In
detail, we found that ZAR1 interferes with S phase pro-
gression of the cell cycle. Further studies are needed to re-
veal through which pathways and by what partners ZAR1
inhibits cancer progression.
Conclusions
Our findings give insight into the properties of ZAR1 in
non-oocyte tissues and its tumour suppressive role in
lung cancer. Together with the observed epigenetic inacti-
vation of ZAR1 in lung cancer and other cancer cell lines,
we propose ZAR1 to be an epigenetically inactivated
tumour suppressor in lung cancer. We demonstrated that
ZAR1 could repress growth of cancer cell lines by inhibit-
ing cell cycle progression. We therefore suggest that in the
future, ZAR1 could serve as a hypermethylated biomarker
for lung cancer detection and possibly could help differen-
tiate between SCLC and NSCLC.
Methods
Analysis of the genomic and protein structure of ZAR1
The promoter region of ZAR1 was analysed by CpG plot
http://www.ebi.ac.uk/Tools/seqstats/emboss_cpgplot/ and
(See figure on previous page.)
Fig. 3 ZAR1 promoter hypermethylation in primary lung tumours and summary of ZAR1 methylation. ZAR1 promoter methylation was studied by
COBRA assay in primary lung tumours of SCLC and NSCLC samples and in normal control tissue. SCLC tumour samples were abbreviated SC and
control tissue N (a). NSCLC tumour samples were abbreviated LT (lung tumours) and control tissue LN. LN1, LN3 and LN39 were matching
samples to tumour samples LT1, LT3 and LT39 (b). CpG island region from the ZAR1 promoter was amplified from bisulfite-treated DNA and
digested with TaqI. Digestion products indicate ZAR1 promoter methylation. Digestion products were separated on 2% TBE agarose gel with
100 bp marker (m methylated, um unmethylated, pos. positive control, + TaqI-digested, − mock digested). c Summary of ZAR1 promoter
methylation in lung cancer cell lines and primary lung tumours is shown (Fisher exact test)
Richter et al. Clinical Epigenetics  (2017) 9:60 Page 6 of 12
ab
c d
Fig. 4 (See legend on next page.)
Richter et al. Clinical Epigenetics  (2017) 9:60 Page 7 of 12
shows the existence of a 1.5 kb large CpG island.
Primers for bisulfite-treated DNA were designed to bind
only fully converted DNA and amplify the promoter re-
gion of ZAR1. The precise promoter region was chosen
for CpG content and presence of according restriction
enzymes for COBRA analysis. The size of the ZAR1
COBRA PCR product is 186 bp (with TaqI site at 89).
Additional file 1: Figure S1 shows an overview of the
ZAR1 gene and protein product, ZAR1 CpG island,
COBRA PCR product, primer positions, TaqI restriction
site and pyrosequencing region.
Cell lines, lung cancer tissues and controls
Lung cancer cell lines (A427, A549, H322, H358, H1299
and HCC15) were described previously [26]. SCLC can-
cer cell lines (CPC-N, DMS-79, H60, H69, H82, H187,
H209, H510, H1092, H1184, H1339, H1963, H2171,
H526, HCC-33, SCLC-21H, SCLC-24H, SCLC-86 M1)
and HCT116 were obtained from Th. Stiewe. All lung
cancer tissues were characterised previously [7, 25, 27].
All patients signed informed consent at initial clinical in-
vestigation. The study was approved by local ethic com-
mittees [7, 25, 27].
(See figure on previous page.)
Fig. 4 Reversal of ZAR1 epigenetic inactivation in cancer cells by demethylation treatment. Various lung cancer cell lines as well as HEK and HeLa
cells were treated with the demethylating agent 5-Aza-2’-deoxycytidine (0, 5 or 10 μM Aza). COBRA assay under Aza treatment shows demethylation
of the ZAR1 promoter (a) and correlating reexpression of ZAR1 levels by semi-quantitative RT-PCR (b). PCR and digestion products were separated on
2% TBE agarose gel with 100 bp marker (m methylated, pm partially methylated, um unmethylated, pos. positive control, + TaqI-digested, − mock
digested). c Real-time PCR quantification of ZAR1 reexpression after 5 μM Aza treatment, which was normalised to GAPDH. d Luciferase reporter assay
was performed to determine the ZAR1 promoter activity. The artificial ZAR1 promoter was cloned into pRLnull and subsequently in vitro methylated.
The promoters were transfected in HeLa cells and the ivm ZAR1 promoter showed full inactivation in contrast to its unmethylated construct and empty
control construct. Student’s t test was used for statistical analysis
a
b
Fig. 5 ZAR1 inhibits colony formation of lung cancer cell lines. ZAR1 was overexpressed in lung cancer cell lines A549, A427 and HTB171 and
ZAR1 inhibited colony formation. Cells were transfected with ZAR1-EGFP or EGFP-vector control. Colonies were selected for 3 weeks with G418
and then Giemsa stained (a, upper panel). The according ZAR1 overexpression was verified by semi-quantitative RT-PCR (a, lower panel). Inhibition
of colony formation by ZAR1 was quantified and showed significant (Student’s t test) reduction in colony numbers (b)
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DNA methylation analysis by COBRA and pyrosequencing
Two microgram genomic DNA (isolation by phenol-
chloroform extraction) from tumour tissue, control tis-
sue and cancer cell lines was bisulfite treated (12 μl
0.1 M hydroquinone, 208 μl 1.9 M sodium metabisulfite
and pH 5.5 with NaOH) and incubated over night at
50 °C. DNA was purified using MSB Spin PCRapace
(STRATEC Molecular), eluted in 50 μl H2O and incu-
bated for 10 min with 5 μl 3 M NaOH at 37 °C. DNA
was then precipitated with 100% ethanol and 7.5 M
ammonium acetate and resolved in 30 μl 1 × TE buffer.
Bisulfite treated DNA was subsequently used for 25 μl
PCR reaction with ZAR1 COBRA primers. The PCR
product was digested with 0.5 μl of TaqI (Thermo Fisher
Scientific) 1 h at 65 °C and resolved on 2% TBE gel
together with mock control. Pyrosequencing was per-
formed according to manufacturer’s protocol with
PyroMark Q24 System (Qiagen). In vitro methylation of
genomic/plasmid DNA for positive control in COBRA
assay and luciferase promoter assay was performed using
CpG methyltransferase M.SssI (NEB) according to man-
ufacturer’s protocol. Primers for COBRA analysis of the
ZAR1 promoter (186 bp) were upper primer GGAG
AAGGAYGAAGAGGGGTTTTT and lower primer
TCCCCCAAAACCRCCATAAAC. For pyrosequencing,
the lower ZAR1 primer was biotinylated. Fisher exact
test was used for statistical analysis.
RNA expression analysis
RNA was isolated using Isol-RNA lysis procedure (5
Prime). RNA was DNase (Thermo Fisher Scientific) treated
and then reversely transcribed by MMLV (Promega). Semi-
quantitative PCR was performed in Eppendorf Mastercycler
using a standard protocol. Quantitative RT–PCR was
performed in triplicate with SYBR select (Thermo Fisher
Scientific) using Rotor-Gene 3000 (Qiagen). Normal human
RNAs were obtained from Agilent Technologies. All other
RNAs were isolated from cultured cancer cell lines. Primers
for RT-PCR were upper primer CCTTCCTTCCTGGG
CATGGAGTC and lower primer CGGAGTACTTGCG
CTCAGGAGGA for ACTB (226 bp), upper primer AGC
TGGGCAAGGAGCGGCTG and lower primer GGTGGG
GCCGTTTAGGGTCCA for ZAR1 (264 bp) and upper pri-
mer TGGAGAAGGCTGGGGCTCAT and lower primer
GACCTTGGCCAGGGGTGCTA for GAPDH (176 bp).
Student’s t test was used for statistical analysis.
Cell culture, demethylation treatment (Aza) and
transfection
Cell lines were grown in appropriate medium (DMEM
or RPMI) supplemented with 10% FCS, and 1% penicil-
lin/streptomycin under cell culture conditions (37 °C,
5% CO2). For 5-Aza-2’deoxycytidine (Aza) treatment
cancer cell lines were split to 10% density, Aza was
added with fresh medium on four consecutive days and
RNA as well as DNA were isolated. For cell line trans-
fection, we used Turbofect (Thermo Fisher Scientific),
X-tremeGENE HP (Roche) or polyethylenimin (Sigma)
with either 4 μg (6-well plates) or 10 μg (10 cm dishes)
of ZAR1-pEGFP, EGFP vector, ZAR1-pRLnull or
pRLnull empty.
Colony formation and cell cycle analysis
For colony formation, assay cells were seeded at 10%
density, transfected the following day. Selection with
G418 (Biochrom) with 2.5 mg/ml (A549) and 0.25 mg/
ml (A427, HTB171) started the following day and con-
tinued for 21 days. After 3 weeks, when visible colonies
formed, cells were dried and stained with Giemsa
(Sigma). Statistical analysis was performed using paired
T test, two-tailed. Regarding flow cytometry analysis,
cells were transfected with ZAR1-pEGFP or EGFP vec-
tor and cells were ethanol fixed after 24 or 48 h as indi-
cated. The following day, fixed cells were PBS washed
and treated with 50 μg/ml RNase A for 30 min at 37 °C.
Subsequently, cells were stained with 50 μg/ml propi-
dium iodide prior to measuring DNA content in FACS-
CantoII (BD Biosciences). FACSDiva Software (BD
Biosciences) was used for measurement/gating to distin-
guish transfected fluorescent cells and to determine cells
in G1/G0, S and G2/M phase of the cell cycle. ZAR1-
EGFP overexpression is shown in HeLa and A549 cells.
Therefore, cells were seeded in 6-well plates on glass
slides and transfected the following day (see above).
Cells were fixed with 3.7% formaldehyde at according
time points, stained with DAPI (0.1 μg/ml in PBS,
Sigma), embedded in anti-fading with Mowiol (Sigma)
and analysed with Axio Observer Z1 (Zeiss) under ×63
magnification and by Volocity Software (Perkin Elmer).
(See figure on previous page.)
Fig. 6 ZAR1 functions as a tumour suppressor in cancer cell lines through cell cycle arrest. a, b Localisation of overexpressed ZAR1 is exemplarily
shown in A549 and HeLa with DAPI nuclear stain (×63 magnification). c–e Flow cytometry analysis found that overexpressed ZAR1 arrests the cell
cycle in HeLa and HCT116 cancer cells. ZAR1 was overexpressed in cancer cells, cells were ethanol-fixed after 24 h (HeLa) and 48 h (HCT116) and
propidium iodide staining was used to determine the DNA content for flow cytometry. The cell cycle distribution of HeLa and HCT116 cells upon
ZAR1 reexpression is quantified (c, e), and gating is exemplarily depicted in HCT116 (d)
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Plasmids and promoter reporter assay
ZAR1 coding sequence was ordered from GeneArt AG
(Regensburg, Germany) and cloned into pEGFP-C2
(Clontech). The ZAR1 promoter (position +526 to −75
relative to transcriptional start site) was amplified from gen-
omic DNA and cloned into pRL-null (Promega). Primers
for cloning the ZAR1 promoter were upper GGAT
CCCTGGGTGGTTCTCCATGCA and lower GAATTCG
TAACCGTCCAGCACCTCGTCCCC (601 bp). All
plasmids were controlled by sequencing, RT-PCR and
immunofluorescence/Western blotting for the expres-
sion vector. For the promoter assay of ZAR1, the Dual-
Luciferase Reporter Assay System (Promega) was used
according to manufacturer’s protocol and HeLa cells were
used. Student’s t test was used for statistical analysis.
Additional files
Additional file 1: Figure S1. Schematic structure of the ZAR1 gene/
protein and CpG island. The ZAR1 gene is shown with its four exons
(encoding an 1275 nt transcript), and its protein (424 aa) structure with a
C-terminal zinc finger (ZF). The ZAR1 CpG island covers 1.5 kb of the
promoter and the first exon. Black vertical lines represent single CpGs,
and the restriction enzyme TaqI recognition site is marked (scissors) for
COBRA methylation assay. Bent arrow indicates transcriptional start site
(TSS). Horizontal arrows mark COBRA methylation analysis PCR product of
186 bp. Methylation analysis by pyrosequencing covers five CpGs (asterisk)
within the COBRA analysed region. 1 kb standard is shown. (PDF 118 kb)
Additional file 2: Table S1. Supplemental Table 1. (XLSX 14 kb)
Additional file 3: Table S2. Supplemental Table 2. (XLSX 13 kb)
Additional file 4: Figure S2. ZAR1 overexpression blocks cell cycle
progression of cancer cell lines. Cell lines HeLa, A549 and HCT116 were
transfected with EGFP or ZAR1-EGFP, isolated after 24 h and fixed with
ethanol. DNA content was measured by FACS CantoII using propidium
iodide staining to determine cell cycle arrest. S phase alteration is marked
in red. A–C Flow cytometry gating is shown for HeLa, A549 and HCT116
cancer cells and D shows quantification for HCT116. (PDF 345 kb)
Additional file 5: Figure S3. Genomic organisation of ZAR1. UCSC
genome browser data revealed that transcription factors as EZH2
(arrowhead) bind to the promoter of ZAR1 as analysed by ChIP-seq by
the ENCODE project. EZH2 binding overlaps with the ZAR1 CpG island
promoter (green) and its first exon (blue). (PDF 576 kb)
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